1. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023) Authors: Liu, Zhigang; Le, Kaixing; Zhou, Xin; Alexander, James L; Lin, Simeng; Bewshea, Claire; Chanchlani, Neil; Nice, Rachel; McDonald, Timothy J; Lamb, Christopher A; Sebastian, Shaji; Kok, Klaartje; Lees, Charlie W; Hart, Ailsa L; Pollok, Richard C; Boyton, Rosemary J; Altmann, Daniel M; Pollock, Kat... Journal: Lancet gastroenterology and hepatology Issue: Volume 8:Number 2(2023) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Issue 10247 (1st August 2020) Authors: Fitzgerald, Rebecca C; di Pietro, Massimiliano; O'Donovan, Maria; Maroni, Roberta; Muldrew, Beth; Debiram-Beecham, Irene; Gehrung, Marcel; Offman, Judith; Tripathi, Monika; Smith, Samuel G; Aigret, Benoit; Walter, Fiona M; Rubin, Greg; Sasieni, Peter; Bagewadi, Abhay; Patrick, Abigail; Shenoy, Ac... Journal: Lancet Issue: Volume 396:Issue 10247(2020) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗